Placeholder

Making Metrics Matter — The Changing Paradigm of R&D Metrics

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 262. Category: .

Product Description

As the pharmaceutical industry comes under greater scrutiny across the board, everything from discovery processes to R&D productivity to profit margins is subject to review. In response, top industry executives are reexamining the efficiency of their R&D operations. In an effort to self-scrutinize, many companies are taking a quantitative approach and reviewing and refining their metrics systems to realize efficiencies and boost R&D productivity, as well as evaluate and motivate their staff.
By defining metrics and collecting data, companies can observe and improve everything from strategic portfolio decisions to resource allocation. Having a historical record, as well as a real-time view of operations, allows executives to make decisions regarding resources, such as staff and technology, and eliminate bottlenecks and overlaps.
Finding efficiencies in R&D can lead to increased productivity, which translates into improvements for both the top and bottom line…

Sidebars:
PharmaVOICE Reader Survey: R&D Metrics
Metrics Versus Milestones

Thought Leaders
Karen Briegs. Director, Marketing and Product Development, 3C Company, Kenilworth, N.J.; 3C Company helps clients achieve strategic advantage by applying industry-specific technology to their business processes. For more information, visit 3cpharma.com.
John A. Cloward. Associate Director, Pfizer Global Research and Development, New London, Conn.; Pfizer discovers, develops, manufactures, and markets leading prescriptions for humans and animals. For more information, visit pfizer.com.
Krish Ghosh, Ph.D., MBA. Director, Project Planning and Information, Wyeth Research, Collegeville, Pa.; Wyeth Research is the research division of Wyeth Pharmaceuticals, a part of Wyeth, a research-based pharmaceutical and healthcare products company. For more information, visit wyeth.com.
Linda Martin. Principal, KMR Group Inc., Chicago; KMR provides consulting services for the international pharmaceutical industry, including pharmaceutical companies, CROs, and biotech companies. For more information, visit kmrgroup.com.
Tom Privette, Ph.D. Senior Director, Global Business Development, Wyeth Pharmaceuticals, Collegeville, Pa.; Wyeth Research is the research division of Wyeth Pharmaceuticals, a part of Wyeth, a research-based pharmaceutical and healthcare products company. For more information, visit wyeth.com.
John D. Rhodes. U.S. and Global Managing Partner, Life Sciences, Deloitte & Touche LLP, Parsippany, N.J.; Deloitte is a professional services firms, providing audit, tax, financial advisory services, and consulting. For more information, visit deloitte.com/us/lifesciences.
Bruce E. Seligmann, Ph.D. Founder, Chairman, and Chief Scientific Officer, High Throughput Genomics Inc., Tucson, Ariz.; HTG provides ArrayPlate qNPA technology and services for the life-sciences industry, addressing current unmet needs and enabling a new era of drug discovery and diagnostics. For more information, visit htgenomics.com.
William K. Sietsema, Ph.D. VP, Clinical and Regulatory Strategic Planning, Kendle, Cincinnati; Kendle is a global CRO delivering clinical-development solutions to help the world’s biopharmaceutical companies maximize product life cycles and grow market share. For more information, visit kendle.com.
Jeffry L. Vaught, Ph.D. Senior VP and President of Research and Development, Cephalon Inc., West Chester, Pa.; Cephalon is an international biopharmaceutical company. For more information, visit cephalon.com.
Ronald S. Waife. President, Waife & Associates Inc., Needham, Mass.; Waife & Associates is a change management consultancy in biopharmaceutical clinical research. For more information, visit waife.com.
Demetris N. Zambas. Associate Director, Clinical Operations, Schering-Plough Research Institute, Schering-Plough Corp., Kenilworth, N.J., Schering-Plough is a global science-based healthcare company with leading prescription, consumer, and animal health products. For more information, visit schering-plough.com.
David S. Zuckerman. President, Customized Improvement Strategies LLC, St. Louis; Customized Improvement Strategies is a management consulting firm that focuses on process improvement, organizational development, leadership development, and change management. For more information, visit rx-business.com.

FEEDBACK